Hire an AI Consultant · Philadelphia, PA

Hire an AI consultant in Philadelphia.

A Chief Compliance Officer at GSK, Independence Blue Cross, or Comcast faces AI strategy questions that general consultants answer incorrectly. The advice is accurate for an unregulated technology company. It misses the specific constraints that apply to pharma, health insurance, and telecommunications.

GSK has EU AI Act obligations for any AI system operating in European markets and FDA guidance implications for AI used in drug development. Independence Blue Cross runs prior authorization AI subject to Section 1557 algorithmic bias requirements. Comcast operates AI systems under FCC oversight and state consumer protection frameworks.

The AI consultant you need knows the OSTP Blueprint for an AI Bill of Rights, FDA's AI/ML SaMD guidance, and what regulators are actually examining in AI governance reviews today, not what the guidance says in theory.

Fixed scope, fixed price, scaled to the scope and the number of regulatory frameworks analyzed.

How we work

Tell us about your AI compliance question.

Pharma: FDA guidance and EU AI Act obligations.

The frameworks that govern AI in drug development are moving faster than most legal teams are tracking. The compliance risk is not current exposure. It is building systems today that create regulatory problems in three years.

FDA AI/ML guidance scope

FDA's primary AI/ML guidance governs Software as a Medical Device in clinical settings. AI used in internal drug development workflows is largely outside current device jurisdiction. The emerging risk is AI-generated clinical evidence in regulatory submissions. If a clinical trial design or biomarker discovery relied on AI, FDA reviewers are beginning to ask about model validation. Build the documentation now.

EU AI Act applicability for US companies

The EU AI Act applies based on where the AI system operates, not where the developer is headquartered. A US pharma company with European clinical trials, European patient-facing AI, or European subsidiary operations has EU AI Act exposure. The high-risk provisions in Annex III cover AI in employment and biometric identification, not drug development directly. The general-purpose AI provisions apply to foundation model usage across the business.

What AI governance documentation pharma needs

For any AI system with potential regulatory contact: model cards documenting training data, validation methodology, and known performance limitations; data lineage records; human oversight procedures; and change management logs. These are not currently required for drug development AI. They will be easier to produce retroactively if the system was built with documentation in mind.

The 3-year regulatory horizon

FDA's 2023 discussion paper on AI in drug manufacturing signaled intent to expand oversight. AI that touches manufacturing processes, quality control, or clinical trial management is the most likely candidate for increased scrutiny. Companies building these capabilities now should treat regulatory documentation as a design requirement, not an afterthought.

Health insurance: HIPAA and algorithmic bias.

AI in prior authorization, care management, and claims processing sits at the intersection of HIPAA, Section 1557 of the ACA, and emerging state-level algorithmic accountability requirements.

HIPAA and AI model training

Using member claims data to train AI models requires a thorough BAA analysis. If the AI vendor is processing PHI during model training or inference, they are a Business Associate. Many AI contracts are written to avoid this classification. The avoidance often creates compliance risk rather than reducing it.

Section 1557 bias obligations

Health insurers must ensure that AI used in covered health programs does not discriminate based on race, color, national origin, sex, age, or disability. The four-fifths rule is a common starting threshold for disparate impact analysis. A prior authorization AI with approval rate disparities above that threshold requires investigation and documentation.

Pennsylvania-specific requirements

The Pennsylvania Human Relations Act applies to health insurance and covers algorithmic discrimination. State insurance commissioner guidance on AI in claims processing is evolving. Independence Blue Cross and other PA payers should track the Pennsylvania Insurance Department's AI workgroup outputs, which have moved faster than federal guidance.

How we work with Philadelphia clients.

Scope before everything

We start with a 45-minute discovery call. Which regulatory frameworks apply, which AI systems are in scope, and what decision needs to be made. Written scope and fixed price before any analysis begins.

Written deliverables, not slide decks

Compliance analysis lives in documents that can be reviewed by legal, shared with regulators, and updated as requirements change. Every engagement produces written work product, not a presentation that expires in 90 days.

Two-week start

We can start within two weeks of a signed agreement. Regulatory deadlines do not wait for procurement cycles. If the timeline is urgent, tell us in the initial call.

Questions we get from Philadelphia clients.

What EU AI Act requirements apply to a US pharma company that sells in Europe, does the AI Act apply to the drug development process?: The EU AI Act applies to AI systems placed on the market or put into service in the EU, regardless of where the developer is based. For a US pharma company like GSK, the relevant question is whether the AI system itself is being deployed in the EU or whether it is used internally in the US to develop a product sold in the EU. AI used purely in internal US drug development workflows is likely outside the Act's direct scope. AI embedded in a product or service delivered to EU customers, or AI that a European subsidiary operates, is in scope. The Act's highest-risk provisions apply to AI used in employment, credit, education, and certain safety-critical domains (not drug development specifically) but AI used in clinical trials conducted in the EU, or patient-facing AI in the European market, warrants close analysis.
What does algorithmic bias review look like for a health insurance AI. What groups are analyzed and what thresholds trigger concern?: A bias review for a health insurance AI starts with defining the protected and proxy attributes relevant to the use case: race, ethnicity, gender, age, disability status, zip code as a socioeconomic proxy, and prior utilization as a care access proxy. For a prior authorization AI, we measure approval rate disparity across these groups using the four-fifths rule as a starting threshold. If the approval rate for any group is less than 80% of the highest-approval group's rate, that disparity warrants investigation. The investigation determines whether the disparity reflects legitimate clinical differences or a pattern that could constitute unlawful discrimination under Section 1557 of the ACA. Independence Blue Cross and other Philadelphia-based payers operating in Pennsylvania are subject to the Pennsylvania Human Relations Act, which applies to health insurance, in addition to federal requirements.
How do you structure an AI governance program for a regulated industry company that also needs to move fast on AI adoption?: The tension between governance and speed is real, but it is usually resolved by being specific about what requires governance. Not every AI deployment needs a full risk review. A chatbot answering customer FAQs on a Comcast support page needs different governance than an AI system that processes insurance claims or recommends clinical protocols. We build tiered governance frameworks: a lightweight checklist for low-stakes, reversible AI deployments; a structured risk assessment for high-stakes deployments; and a formal approval process for deployments that affect regulated decisions. Most organizations trying to move fast are slowing themselves down by applying the same process to every use case. The fix is calibration, not less governance.
What's the difference between what FDA currently requires for AI in drug development vs. what it might require in 3 years?: Currently, FDA's primary AI/ML guidance focuses on Software as a Medical Device used in clinical settings, diagnostic aids, clinical decision support. AI used in drug development workflows (compound screening, trial design optimization, biomarker discovery) is largely unregulated as AI. FDA evaluates the drug, not the AI that helped develop it. The emerging area is AI-generated clinical evidence: if a drug application relies on AI-synthesized data or AI-assisted trial design, FDA reviewers are beginning to ask questions about model validation and data provenance. The FDA's 2023 discussion paper on AI in drug manufacturing signaled interest in expanded oversight. Companies building internal AI capabilities for drug development now should maintain model documentation and validation records that could support regulatory scrutiny in 3-5 years.

Bring the regulatory picture into focus.

Tell us which AI system or regulatory question is most pressing. We reply within one business day with a rough scope and price range. No commitment required.

Hire an AI consultant in Philadelphia.

Fixed scope, fixed price, scaled to the scope and the number of regulatory frameworks analyzed.

Pharma: FDA guidance and EU AI Act obligations.

FDA AI/ML guidance scope

EU AI Act applicability for US companies

What AI governance documentation pharma needs

The 3-year regulatory horizon

Health insurance: HIPAA and algorithmic bias.

AI in prior authorization, care management, and claims processing sits at the intersection of HIPAA, Section 1557 of the ACA, and emerging state-level algorithmic accountability requirements.

HIPAA and AI model training

Section 1557 bias obligations

Pennsylvania-specific requirements

How we work with Philadelphia clients.

Scope before everything

Written deliverables, not slide decks

Two-week start

We can start within two weeks of a signed agreement. Regulatory deadlines do not wait for procurement cycles. If the timeline is urgent, tell us in the initial call.

Questions we get from Philadelphia clients.

What EU AI Act requirements apply to a US pharma company that sells in Europe, does the AI Act apply to the drug development process?

The EU AI Act applies to AI systems placed on the market or put into service in the EU, regardless of where the developer is based. For a US pharma company like GSK, the relevant question is whether the AI system itself is being deployed in the EU or whether it is used internally in the US to develop a product sold in the EU. AI used purely in internal US drug development workflows is likely outside the Act's direct scope. AI embedded in a product or service delivered to EU customers, or AI that a European subsidiary operates, is in scope. The Act's highest-risk provisions apply to AI used in employment, credit, education, and certain safety-critical domains (not drug development specifically) but AI used in clinical trials conducted in the EU, or patient-facing AI in the European market, warrants close analysis.

What does algorithmic bias review look like for a health insurance AI. What groups are analyzed and what thresholds trigger concern?

A bias review for a health insurance AI starts with defining the protected and proxy attributes relevant to the use case: race, ethnicity, gender, age, disability status, zip code as a socioeconomic proxy, and prior utilization as a care access proxy. For a prior authorization AI, we measure approval rate disparity across these groups using the four-fifths rule as a starting threshold. If the approval rate for any group is less than 80% of the highest-approval group's rate, that disparity warrants investigation. The investigation determines whether the disparity reflects legitimate clinical differences or a pattern that could constitute unlawful discrimination under Section 1557 of the ACA. Independence Blue Cross and other Philadelphia-based payers operating in Pennsylvania are subject to the Pennsylvania Human Relations Act, which applies to health insurance, in addition to federal requirements.

How do you structure an AI governance program for a regulated industry company that also needs to move fast on AI adoption?

The tension between governance and speed is real, but it is usually resolved by being specific about what requires governance. Not every AI deployment needs a full risk review. A chatbot answering customer FAQs on a Comcast support page needs different governance than an AI system that processes insurance claims or recommends clinical protocols. We build tiered governance frameworks: a lightweight checklist for low-stakes, reversible AI deployments; a structured risk assessment for high-stakes deployments; and a formal approval process for deployments that affect regulated decisions. Most organizations trying to move fast are slowing themselves down by applying the same process to every use case. The fix is calibration, not less governance.

What's the difference between what FDA currently requires for AI in drug development vs. what it might require in 3 years?

Currently, FDA's primary AI/ML guidance focuses on Software as a Medical Device used in clinical settings, diagnostic aids, clinical decision support. AI used in drug development workflows (compound screening, trial design optimization, biomarker discovery) is largely unregulated as AI. FDA evaluates the drug, not the AI that helped develop it. The emerging area is AI-generated clinical evidence: if a drug application relies on AI-synthesized data or AI-assisted trial design, FDA reviewers are beginning to ask questions about model validation and data provenance. The FDA's 2023 discussion paper on AI in drug manufacturing signaled interest in expanded oversight. Companies building internal AI capabilities for drug development now should maintain model documentation and validation records that could support regulatory scrutiny in 3-5 years.

Bring the regulatory picture into focus.

Tell us which AI system or regulatory question is most pressing. We reply within one business day with a rough scope and price range. No commitment required.